Neoadjuvant endocrine therapy is increasingly used in patients that share clinicopathological characteristics such as: high ER and PR, low Ki67, HER-2 negative, large tumor size, advanced age [1, 2] or presence of comorbidities that preclude surgery. This evidence concerns the gene ESR1 and neoplasm.